Concepedia

Author

Hirohisa Nakamae

Osaka City UniversityORCID

Also Known As

H Nakamae, H. Nakamae, H., Nakamae, HIROHISA NAKAMAE, Hajime Sumi, Hirohisa NAKAMAE, Hirohisa Nakamae, Ken-ichi Matsuoka, Nakamae Hirohisa, Shuichi Ota

481

Publications

8.6K

Citations

37

H-Index

120

Concepts

All Affiliations

Osaka City UniversityTokyo Metropolitan Komagome HospitalThe Japanese Data Center for Hematopoietic Cell TransplantationNagoya UniversityToranomon Hospital
HN

About

Hirohisa Nakamae is an author at Osaka City University specializing in medicine, hematology, and health sciences.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

28

73

3.1K

2

Health Sciences

22

36

1.8K

3

Natural Sciences

1

1

68

4

Biochemistry

1

1

68

5

Biostatistics

1

1

28

Hirohisa Nakamae

×

139

Publications

7.6K

Citations

36

H-Index

YearCitations

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Hagop M. Kantarjian, Neil P. Shah, Andreas Hochhaus,

New England Journal of Medicine

2010

1.6K

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Andreas Hochhaus, Giuseppe Saglio, Timothy P. Hughes,

Leukemia

2016

841

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

Hagop M. Kantarjian, Andreas Hochhaus, Giuseppe Saglio,

The Lancet Oncology

2011

511

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

Jun Imagawa, Hideo Tanaka, Masaya Okada,

The Lancet Haematology

2015

297

Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone

Hirohisa Nakamae, Kei Tsumura, Yoshiki Terada,

Cancer

2005

241

Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group

Katsuto Takenaka, Tetsuya Nishida, Yuki Asano‐Mori,

Biology of Blood and Marrow Transplantation

2015

190

The critical role of CD4+ T cells in PD-1 blockade against MHC-II–expressing tumors such as classic Hodgkin lymphoma

Joji Nagasaki, Yosuke Togashi, Takeaki Sugawara,

Blood Advances

2020

118

Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment

Masaya Okada, Jun Imagawa, Hideo Tanaka,

Clinical Lymphoma Myeloma & Leukemia

2018

116

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

Richard A. Larson, Ophelia Yin, Andreas Hochhaus,

European Journal of Clinical Pharmacology

2011

107

Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse

Saiko Kurosawa, T Yamaguchi, S Miyawaki,

Haematologica

2010

107

Page 1